Urgent ERCP with pancreatic stent placement or replacement for salvage of post-ERCP pancreatitis

Tossapol Kerdsirichairat; Rajeev Attam; Mustafa Arain; Yan Bakman; David Radosevich; Martin Freeman

doi:10.1055/s-0034-1377750

Endoscopy, Table of Contents

Endoscopy 2014; 46(12): 1085-1094
DOI: 10.1055/s-0034-1377750

Original article

Urgent ERCP with pancreatic stent placement or replacement for salvage of post-ERCP pancreatitis

Authors

Tossapol Kerdsirichairat

¹Division of Gastroenterology, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States
Rajeev Attam

¹Division of Gastroenterology, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States
Mustafa Arain

¹Division of Gastroenterology, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States
Yan Bakman

¹Division of Gastroenterology, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States
David Radosevich

²Department of Surgery, University of Minnesota, Minneapolis, Minnesota, USA
Martin Freeman

¹Division of Gastroenterology, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States

Abstract

Background and study aims: Urgent placement or replacement of pancreatic stents shortly after endoscopic retrograde cholangiopancreatography (ERCP) might attenuate the course of evolving post-ERCP pancreatitis (PEP).

Patients and methods: Salvage ERCP with de novo pancreatic stent placement or replacement of outwardly migrated stents was performed within 2 – 48 hours in patients with evolving PEP accompanied by severe pain, systemic inflammatory response syndrome (SIRS), and major elevations in serum amylase and lipase. Serial pain scores, amylase and lipase levels, and hospital course were studied.

Results: PEP according to Cotton consensus criteria developed after 64 (2 %) of 3216 ERCPs over 3 years. Of the 64 patients with PEP, 14 underwent salvage ERCP (5 without and 9 with prior pancreatic stents, 7 of which had migrated outwards prematurely). All patients had SIRS and a high score (≥ 3) for the bedside index for severity in acute pancreatitis. Median clinical onset of PEP was at 5 hours (range 0 – 68 hours) in patients with prophylactic pancreatic stents vs. 2 hours (range 0.5 – 2.5 hours) in patients without prophylactic pancreatic stents (P < 0.05). Salvage ERCP was performed at a median of 10 hours (interquartile range [IQR] 2.4 – 22.7 hours). Improvement in pain, amylase, lipase, and resolution of SIRS were statistically significant at 24 hours after salvage ERCP (P = 0.003). Median length of hospital stay was 2 days (IQR 1 – 4.75). No necrotizing pancreatitis or late complications occurred.

Conclusion: Urgent salvage ERCP with de novo pancreatic stent placement or replacement of a migrated stent is a novel approach in the setting of early PEP, and was associated with rapid resolution of clinical pancreatitis and reduction in levels of amylase and lipase.

Full Text

References

References
1 Dumonceau JM, Andriulli A, Deviere J et al. European Society of Gastrointestinal Endoscopy (ESGE) guideline: Prophylaxis of post-ERCP pancreatitis. Endoscopy 2010; 42: 503-515
2 Freeman ML, Nelson DB, Sherman S et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996; 335: 909-918
3 Masci E, Toti G, Mariani A et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol 2001; 96: 417-423
4 Mehta SN, Pavone E, Barkun JS et al. Predictors of post-ERCP complications in patients with suspected choledocholithiasis. Endoscopy 1998; 30: 457-463
5 Loperfido S, Angelini G, Benedetti G et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc 1998; 48: 1-10
6 Safrany L. Endoscopic treatment of biliary-tract diseases. An international study. Lancet 1978; II: 983-985
7 Friedland S, Soetikno RM, Vandervoort J et al. Bedside scoring system to predict the risk of developing pancreatitis following ERCP. Endoscopy 2002; 34: 483-488
8 Rabenstein T, Schneider HT, Bulling D et al. Analysis of the risk factors associated with endoscopic sphincterotomy techniques: preliminary results of a prospective study, with emphasis on the reduced risk of acute pancreatitis with low-dose anticoagulation treatment. Endoscopy 2000; 32: 10-19
9 Vandervoort J, Soetikno RM, Tham TCK et al. Risk factors for complications after performance of ERCP. Gastrointest Endosc 2002; 56: 652-656
10 Andriulli A, Clemente R, Solmi L et al. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc 2002; 56: 488-495
11 Cotton PB, Garrow DA, Gallagher J et al. Risk factors for complications after ERCP: a multivariate analysis of 11,497 procedures over 12 years. Gastrointest Endosc 2009; 70: 80-88
12 Freeman ML, DiSario JA, Nelson DB et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 2001; 54: 425-434
13 Freeman ML. Complications of endoscopic retrograde cholangiopancreatography: avoidance and management. Gastrointest Endosc Clin N Am 2012; 22: 567-586
14 Enestvedt BK, Ahmad NA. Pancreatic duct stents for the prevention of post ERCP pancreatitis: for all or some?. Gastroenterology 2012; 143: 493-500
15 Choudhary A, Bechtold ML, Arif M et al. Pancreatic stents for prophylaxis against post-ERCP pancreatitis: a meta-analysis and systematic review. Gastrointest Endosc 2011; 73: 275-282
16 Fazel A, Quadri A, Catalano MF et al. Does a pancreatic duct stent prevent post-ERCP pancreatitis? A prospective randomized study. . Gastrointest Endosc 2003; 57: 291-294
17 Harewood GC, Pochron NL, Gostout CJ. Prospective, randomized, controlled trial of prophylactic pancreatic stent placement for endoscopic snare excision of the duodenal ampulla. Gastrointest Endosc 2005; 62: 367-370
18 Sofuni A, Maguchi H, Mukai T et al. Endoscopic pancreatic duct stents reduce the incidence of post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients. Clin Gastroenterol Hepatol 2011; 9: 851-858
19 Tarnasky PR, Palesch YY, Cunningham JT et al. Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients with sphincter of Oddi dysfunction. Gastroenterology 1998; 115: 1518-1524
20 Lee TH, Moon JH, Choi HJ et al. Prophylactic temporary 3F pancreatic duct stent to prevent post-ERCP pancreatitis in patients with a difficult biliary cannulation: a multicenter, prospective, randomized study. Gastrointest Endosc 2012; 76: 578-585
21 Das A, Singh P, Sivak Jr MV et al. Pancreatic-stent placement for prevention of post-ERCP pancreatitis: a cost-effectiveness analysis. Gastrointest Endosc 2007; 65: 960-968
22 Freeman ML, Guda NM. Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc 2004; 59: 845-864
23 Linder JD, Tarnasky PR. Treatment of post-ERCP pancreatitis with ERCP. Am J Gastroenterol 2005; 100 : S234
24 Hisai H, Hirako T, Arihara Y et al. Urgent ERCP with pancreatic duct stent placement for the management of post-ERCP pancreatitis: results of large case series at the district central hospital in Japan. Gastrointest Endosc 2014; 79 : AB367-368
25 Madácsy L, Kurucsai G, Joó I et al. Rescue ERCP and insertion of a small-caliber pancreatic stent to prevent the evolution of severe post-ERCP pancreatitis: a case-controlled series. Surg Endosc 2009; 23: 1887-1893
26 Banks PA, Bollen TL, Dervenis C et al. Classification of acute pancreatitis – 2012: revision of the Atlanta classification and definitions by international consensus. Gut 2013; 62: 102-111
27 Muckart DJ, Bhagwanjee S. American College of Chest Physicians/Society of Critical Care Medicine consensus conference definitions of the systemic inflammatory response syndrome and allied disorders in relation to critically injured patients. Crit Care Med 1997; 25: 1789-1795
28 Mofidi R, Duff MD, Wigmore SJ et al. Association between early systemic inflammatory response, severity of multiorgan dysfunction and death in acute pancreatitis. Br J Surg 2006; 93: 738-744
29 Wu BU, Johannes RS, Sun X et al. The early prediction of mortality in acute pancreatitis: a large population-based study. Gut 2008; 57: 1698-1703
30 Papachristou GI, Muddana V, Yadav D et al. Comparison of BISAP, Ranson’s, APACHE-II, and CTSI scores in predicting organ failure, complications, and mortality in acute pancreatitis. Am J Gastroenterol 2010; 105: 435-441
31 Gompertz M, Fernandez L, Lara I et al. Bedside index for severity in acute pancreatitis (BISAP) score as predictor of clinical outcome in acute pancreatitis: retrospective review of 1128 patients. Rev Med Chil 2012; 140: 977-983
32 Elmunzer BJ, Scheiman JM, Lehman GA et al. A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med 2012; 366: 1414-1422
33 Freeman ML. Pancreatic stents for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Clin Gastroenterol Hepatol 2007; 5: 1354-1365
34 Kozarek RA. Balloon dilation of the sphincter of Oddi. Endoscopy 1988; 20: 207-210
35 Smithline A, Silverman W, Rogers D et al. Effect of prophylactic main pancreatic duct stenting on the incidence of biliary endoscopic sphincterotomy-induced pancreatitis in high-risk patients. Gastrointest Endosc 1993; 39: 652-657
36 Singh P, Das A, Isenberg G et al. Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials. . Gastrointest Endosc 2004; 60: 544-550
37 Mazaki T, Mado K, Masuda H et al. Prophylactic pancreatic stent placement and post-ERCP pancreatitis: an updated meta-analysis. J Gastroenterol 2014; 49: 343-355
38 Andriulli A, Forlano R, Napolitano G et al. Pancreatic duct stents in the prophylaxis of pancreatic damage after endoscopic retrograde cholangiopancreatography: a systematic analysis of benefits and associated risks. Digestion 2007; 75: 156-163
39 Freeman ML. Pancreatic stents for prevention of post-ERCP pancreatitis: for everyday practice or for experts only?. Gastrointest Endosc 2010; 71: 940-944
40 Ito K, Fujita N, Kanno A et al. Risk factors for post-ERCP pancreatitis in high risk patients who have undergone prophylactic pancreatic duct stenting: a multicenter retrospective study. Intern Med 2011; 50: 2927-2932
41 Johnson CD, Abu-Hilal M. Persistent organ failure during the first week as a marker of fatal outcome in acute pancreatitis. Gut 2004; 53: 1340-1344
42 Singh VK, Wu BU, Bollen TL et al. Early systemic inflammatory response syndrome is associated with severe acute pancreatitis. Clin Gastroenterol Hepatol 2009; 7: 1247-1251
43 Elmunzer BJ, Waljee AK, Elta GH et al. A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis. Gut 2008; 57: 1262-1267
44 Zheng MH, Xia HH, Chen YP. Rectal administration of NSAIDs in the prevention of post-ERCP pancreatitis: a complementary meta-analysis. Gut 2008; 57: 1632-1633
45 Akbar A, Abu Dayyeh BK, Baron TH et al. Rectal nonsteroidal anti-inflammatory drugs are superior to pancreatic duct stents in preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a network meta-analysis. Clin Gastroenterol Hepatol 2013; 11: 778-783
46 Brackbill S, Young S, Schoenfeld P et al. A survey of physician practices on prophylactic pancreatic stents. Gastrointest Endosc 2006; 64: 45-51
47 Chahal P, Tarnasky PR, Petersen BT et al. Short 5Fr vs long 3Fr pancreatic stents in patients at risk for post-endoscopic retrograde cholangiopancreatography pancreatitis. Clin Gastroenterol Hepatol 2009; 7: 834-839
48 Afghani E, Akshintala VS, Khashab MA et al. 5-Fr vs. 3-Fr pancreatic stents for the prevention of post-ERCP pancreatitis in high-risk patients: a systematic review and network meta-analysis. Endoscopy 2014; 46: 573-580
49 Freeman ML, Overby CS, Qi DF. Pancreatic stent insertion: consequences of failure, and results of a modified technique to maximize success. Gastrointest Endosc 2004; 59: 8-14

Supplementary Material

Supplementary material (PDF)